



PCT


WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 403/14, A61K 31/40		A1	(11) International Publication Number: WO 98/04551 (43) International Publication Date: 5 February 1998 (05.02.98)
(21) International Application Number:	PCT/EP97/03888	(81) Designated States:	AU, BR, CA, CN, CZ, HU, IL, JP, KR, MX, NO, NZ, PL, RU, SG, TR, YU, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
(22) International Filing Date:	19 July 1997 (19.07.97)	Published	<i>With international search report.</i>
(30) Priority Data:	60/022,078 60/048,496	29 July 1996 (29.07.96) 3 June 1997 (03.06.97)	US US
(71) Applicant:	F. HOFFMANN-LA ROCHE AG [CH/CH]; 124, Grenzacherstrasse, CH-4070 Basle (CH).		
(72) Inventors:	DHINGRA, Urvashi, Hooda; 82 Beech Street, Nutley, NJ 07110 (US). HURYN, Donna, Mary; 8 Tyler Court, Allentown, NJ 08501 (US). KEITH, Dennis, Dalton; 8 Mendel Terrace, Montclair, NJ 07042 (US).		
(74) Agent:	MEZGER, Wolfgang; 124, Grenzacherstrasse, CH-4070 Basle (CH).		

(54) Title: SUBSTITUTED BISINDOLYLMALEIMIDES FOR THE INHIBITION OF CELL PROLIFERATION



(57) Abstract

Compounds of formula (I) wherein: R¹ and R^{1'} are independently alkyl, aryl, alkenyl or alkynyl; R² and R^{2'} are independently hydrogen, alkyl, aralkyl, alkoxyalkyl, hydroxylalkyl, haloalkyl, aminoalkyl, monoalkylaminoalkyl, dialkylaminoalkyl, acylaminoalkyl, alkylsulphonylaminoalkyl, arylsulphonyl-aminoalkyl, mercaptoalkyl, alkylthioalkyl, carboxyalkyl, alkoxycarbonylalkyl, aminocarbonylalkyl, alkylthio or alkylsulphiny; R⁴, R⁵, R⁶, R⁷, R^{4'}, R^{5'}, R^{6'} and R^{7'} each independently are hydrogen, formula (II), CO₂R⁹, CH₂OR¹⁰, CHO, CH₂NR¹¹R¹², CON(R¹³)₂, halogen, cyano, aryl, alkyl, hydroxy, alkoxy, aryloxy, haloalkyl, nitro, amino, aralkyloxy, acylamino, monoalkylamino, dialkylamino, thio, alkylthio, alkylsulphiny, alkylsulphonyl, arylsulphiny, azide, phosphate or phosphonate provided that at least one of R⁴, R⁵, R⁶ and R⁷ and at least one of R^{4'}, R^{5'}, R^{6'} and R^{7'} are other than hydrogen, with the proviso that when R⁶ is methoxy, R⁵ or R^{5'} are not methoxy; R⁸ is alkyl or aryl; R⁹ is alkyl or aryl; R¹⁰ is hydrogen, alkyl or aryl; R¹¹ and R¹² are independently hydrogen, alkyl, aryl, aralkyl or acyl; R¹³ is hydrogen, alkyl, aryl or aralkyl; and one of X and Y signifies O and the other signifies O, S, (H₂O) or (H,H); as well as pharmaceutically acceptable prodrugs therefor or pharmaceutically acceptable salts of acidic compounds of formula (I) with basis or basic compounds of formula (I) with acids are antiproliferative agents useful in the treatment of cancer.


Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

FOR THE PURPOSES OF INFORMATION ONLY

SUBSTITUTED BISINDOLYLMALEIMIDES FOR THE INHIBITION OF CELL PROLIFERATION

The invention relates to substituted pyrroles. More particularly, the invention relates to substituted pyrroles of the formula

5



I

wherein

R¹ and R^{1'} are independently alkyl, aryl, alkenyl or alkynyl;

R² and R^{2'} are independently hydrogen or alkyl;

- 10 R⁴, R⁵, R⁶, R⁷, R^{4'}, R^{5'}, R^{6'}, and R^{7'} each independently are hydrogen, CH₂OCCR⁸, CO₂R⁹, CH₂OR¹⁰, CHO, CH₂NR¹¹R¹², CON(R¹³)₂, halogen, cyano, aryl, aralkyloxy, alkyl, hydroxy, alkoxy, aryloxy, haloalkyl, nitro, amino, aralkyloxy, acylamino, monoalkylamino, dialkylamino, thio, alkylthio, alkylsulphinyl, alkylsulphonyl, arylsulphinyl, azide, phosphate or phosphonate provided that at least one of R⁴, R⁵, R⁶ and R⁷ and at least one of R^{4'}, R^{5'}, R^{6'}, and R^{7'} are other than hydrogen;
- 15 R⁸ is alkyl or aryl;
- R⁹ is alkyl or aryl;
- R¹⁰ is hydrogen, alkyl or aryl;
- 20 R¹¹ and R¹² are independently hydrogen, alkyl, aryl, aralkyl or acyl;
- R¹³ is hydrogen, alkyl, aryl or aralkyl; and



2

one of X and Y signifies O and the other signifies O, S, (H,OH) or (H,H); with the proviso that when R⁶ is methoxy, R⁵ or R^{5'} are not methoxy, as well as pharmaceutically acceptable prodrugs therefor or pharmaceutically acceptable salts of acidic compounds of formula I with bases or basic compounds of formula I with acids.

5 The compounds of the invention are anti-proliferative agents usefuls in the treatment or control of cancer, particularly in the treatment or control of solid tumors. The compounds of the invention are especially useful in the treatment or
10 control of breast tumors.

As used herein, the term "alkyl", alone or in combinations, means a straight or branched-chain alkyl group containing a maximum of 10, preferably a maximum of 5, carbon atoms such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, t-butyl and pentyl which is unsubstituted or substituted by one or more substituents selected from the group consisting of hydroxy, alkoxy, amino, halogen, thioalkyl or alkylsulphanyl. The term „alkoxy“ denotes a group wherein the alkyl residue is as defined above, for example, methoxy, ethoxy, propoxy, isopropoxy, butoxy, t-butoxy and the like. A haloalkyl group can carry one or more halogen atoms, with examples of such groups being chloromethyl and trifluoromethyl. The term „acyl“, alone or in combination, means a group derived from an alkanoic acid containing a maximum of 10, preferably a maximum of 5, carbon atoms for example, acetyl, propionyl or butyryl, or from an aromatic carboxylic acid for example, benzoyl.
15 Examples of substituents on alkanoic acid include one or more of the following:
20 hydroxy, alkoxy, amino, halogen, thioalkyl, carboxy, carboxylic acid derivative or alkyl sulphanyl and the like. Examples of substituents on aromatic carboxylic acid include one or more of the following: halogen, alkyl, hydroxy, benzyloxy, alkoxy, haloalkyl, nitro, amino, cyano and the like. The term "aryl", alone or in
25 combinations means an unsubstituted phenyl group or a phenyl group carrying one or more, preferably one to three, substituents, examples of which are halogen, alkyl, hydroxy, benzyloxy, alkoxy, haloalkyl, nitro, amino and cyano. The term "halogen"
30 means fluorine, chlorine, bromine or iodine. The term „amino“, alone or in combination means an unsubstituted amine group or an amine substituted by one or more substituents selected from alkyl, aryl, acyl, alkylsulfonyl or arylsulfonyl . The term „alkenyl“ refers to straight or branched chain hydrocarbon groups of 2 to 5
35

3

carbon atoms having at least one double bond. Groups of 3 to 5 carbon atoms are preferred. The term „alkynyl“ refers to straight or branched chain groups of 2 to 5 carbon atoms having at least one triple bond. Groups of 3 to 5 carbon atoms are preferred.

5

The term „amino protecting group“ means any conventional amino protecting group such as alkyl, preferably methyl, substituted alkyl, such as trityl and trialkylsilyleethyl, acyl and the like.

10

As used herein, the term „pharmaceutically acceptable prodrug“ means a compound that may be converted under physiological conditions or by solvolysis to a compound of formula I or to a pharmaceutically acceptable salt thereof.

15

In formula I above, R¹ and R^{1'} are preferably alkyl. In an especially preferred embodiment, R¹ and R^{1'} are methyl. Preferably, R² and R^{2'} are hydrogen.

At least one of R⁴, R⁵, R⁶ and R⁷ and at least one of R^{4'}, R^{5'} R^{6'}


and R⁷ are preferably nitro, alkoxy, alkyl, halogen, cyano, CH₂OCCR⁸, CO₂R⁹, CH₂OR¹⁰, CH₂NR¹¹R¹², CHO, CON(R¹³)₂, alkylthio or aralkyloxy.

20

In a preferred embodiment, at least one of

R⁴, R⁵, R⁶, R⁷ and one of R^{4'}, R^{5'} R^{6'} and R⁷ are cyano, CH₂OCCR⁸, CO₂R⁹, CH₂OR¹⁰, CH₂NR¹¹R¹², CHO, or CON(R¹³)₂.

25

In a particularly preferred embodiment, one of R⁴, R⁵, R⁶, R⁷ and one of R^{4'}, R^{5'}, R^{6'} and R⁷ are nitro, alkoxy, alkyl, halogen,


 cyano, CH₂OCCR⁸, CO₂R⁹, CH₂OR¹⁰, CH₂NR¹¹R¹², CHO, CON(R¹³)₂, alkylthio, or aralkyloxy and the others are hydrogen.

30

In an especially preferred embodiment, R⁶ and R^{6'} are independently nitro,

4



alkoxy, alkyl, halogen, cyano, CH_2OCR^8 , CO_2R^9 , $\text{CH}_2\text{OR}^{10}$, $\text{CH}_2\text{NR}^{11}\text{R}^{12}$, alkylthio, aralkyloxy, CHO or $\text{CON}(\text{R}^{13})_2$, and R^4 , R^5 , R^7 and $\text{R}^{4'}$, $\text{R}^{5'}$ and $\text{R}^{7'}$ are hydrogen.

5 Preferably R^8 and R^9 are independently alkyl, particularly preferred is methyl, R^{10} is hydrogen or alkyl, preferably methyl, R^{11} and R^{12} are hydrogen or alkyl and R^{13} is hydrogen or alkyl.

Preferred compounds of formula I are those in which R^1 and $\text{R}^{1'}$ are alkyl; R^2 and $\text{R}^{2'}$ are hydrogen, at least one R^4 , R^5 , R^6 and R^7 and at least one of $\text{R}^{4'}$, $\text{R}^{5'}$, $\text{R}^{6'}$



10 and $\text{R}^{7'}$ are nitro, alkoxy, alkyl, halogen, cyano, CH_2OCR^8 , CO_2R^9 , $\text{CH}_2\text{OR}^{10}$, $\text{CH}_2\text{NR}^{11}\text{R}^{12}$, CHO, $\text{CON}(\text{R}^{13})_2$, alkylthio, or aralkyloxy, R^8 and R^9 are alkyl; R^{10} is alkyl; R^{11} and R^{12} are alkyl; and R^{13} is alkyl.

15 In a particularly preferred embodiment, R^1 and $\text{R}^{1'}$ are methyl; R^2 and $\text{R}^{2'}$ are hydrogen, one of R^4 , R^5 , R^6 , R^7 and one of $\text{R}^{4'}$, $\text{R}^{5'}$, $\text{R}^{6'}$ and $\text{R}^{7'}$ is nitro, alkoxy, alkyl,



halogen, cyano, CH_2OCR^8 , CO_2R^9 , $\text{CH}_2\text{OR}^{10}$, alkylthio, aralkyloxy, $\text{CH}_2\text{NR}^{11}\text{R}^{12}$, CHO or $\text{CON}(\text{R}^{13})_2$ and the others are hydrogen; R^8 and R^9 are methyl; R^{10} is methyl; R^{11} and R^{12} are methyl; and R^{13} is methyl.

20 In another preferred embodiment, R^1 and $\text{R}^{1'}$ are alkyl; R^2 and $\text{R}^{2'}$ are hydrogen, at least one of R^4 , R^5 , R^6 and R^7 is amino, acylamino, monoalkylamino or dialkylamino.

25 In a particularly preferred embodiment, R^1 and $\text{R}^{1'}$ are alkyl; R^2 and $\text{R}^{2'}$ are hydrogen, R^6 is amino, acylamino, monoalkylamino or dialkylamino and at least one of R^4 , R^5 and R^6 is




CH_2OCR^8 , CO_2R^9 , $\text{CH}_2\text{OR}^{10}$, CHO, $\text{CH}_2\text{NR}^{11}\text{R}^{12}$, $\text{CON}(\text{R}^{13})_2$, halogen, cyano, aryl, alkyl, hydroxy, alkoxy, aryloxy, haloalkyl, nitro, amino, aralkyloxy, acylamino,

5

monoalkylamino, dialkylamino, thio, alkylthio, alkylsulphanyl, alkylsulphonyl, arylsulphanyl, azide, phosphate or phosphonate.


In a more preferred embodiment, R¹ and R^{1'} are alkyl; R² and R^{2'} are hydrogen, R⁶ is amino, acylamino, monoalkylamino or dialkylamino and R⁶ is



10 cyano, alkylthio, alkyl, nitro or acylamino.

The compounds of formula I in which X and Y both signify O, are prepared by the following Schemes 1-3.

6

SCHEME I

5


wherein R^1 , R^2 , R^4 , R^5 , R^6 and R^7 are as described above; provided that when any of R^1 - R^7 are substituents which react with acid chlorides, such as, for example, when any of R^1 - R^7 are hydroxy, hydroxylalkyl, amino, monoalkylamino or aminoalkyl, such substituent is protected with a conventional protecting group.

7

As set forth in Scheme 1, a compound of formula II, a known compound or compound prepared by known methods, is reacted with NaH and CH₃I in an inert solvent, such as N,N-dimethylformamide or tetrahydrofuran at a temperature of from about 0°C to about 25°C, to form a corresponding compound of formula III.

5

A compound of formula III is reacted with oxalyl chloride in a solvent such as diethyl ether (Et₂O) or dichloromethane (CH₂Cl₂) at a temperature of from 0°C to 25°C to form a corresponding compound of formula IV.



wherein R^1 , R^2 , R^4 , R^5 , R^6 , R^7 , $R^{1'}$, $R^{2'}$, $R^{4'}$, $R^{5'}$, $R^{6'}$ and $R^{7'}$ are as described above; provided that when any of R^1 - R^7 or $R^{1'}$ - $R^{7'}$ are substituents, which

react with acid chlorides, such as, for example, when any of R¹-R⁷ or R^{1'}-R⁷ are hydroxy, hydroxyalkyl, amino, monoalkylamino or aminoalkyl, such substituent is protected with a conventional protecting group.

5 As set forth in Scheme 2, a compound of formula V, a known compound or compound prepared by known methods, is reacted with POCl₃ in N,N-dimethylformamide (DMF) at a temperature of from 0°C to 60°C to form a corresponding compound of formula VI.

10 A compound of formula VI is reacted with NaH and CH₃I in an inert solvent, such as, dimethylformamide or THF to form a corresponding compound of formula VII.

15 A compound of formula VII is reacted with potassium tert-butoxide (KOtBu) and toluene-4-sulfonyl methyl isocyanide (TosMIC) in a solvent, such as, ethylene glycol-dimethylether (DME) at a temperature between -30°C and -60°C, then treated with methanol at a temperature of 65°C to form a corresponding compound of formula VIII.

20 A compound of formula VIII is reacted with HCl gas in isopropanol to form a corresponding compound of formula IX.


25 A compound of formula IX is reacted with a compound of formula IV and Et₃N in a solvent such as methylene chloride at a temperature between 0°C to 25°C. The resultant product is then treated with para-toluene sulphonic acid (pTsOH) in a solvent such as toluene at a temperature of about 25°C to form a corresponding compound of formula I. If a protecting group was utilized during the reaction of IX and IV, it is removed at this point using methods known in the art.

30 Alternatively and preferably, to prepare a compound of formula I wherein R⁴, R⁵, R⁶, R⁷, R^{4'}, R^{5'}, R^{6'}, R^{7'} are amino, alkylamino, dialkylamino or acylamino, a precursor bis-indolylmaleimide of formula I wherein R⁴, R⁵, R⁶, R⁷, R^{4'}, R^{5'}, R^{6'} or R^{7'} is nitro, is reduced by methods known in the art to form a corresponding amino bis-indolylmaleimide. The amino group is then modified to the desired alkylamino, dialkyl or acylamino derivative by methods known in the art.

10

Compounds of formula I wherein R¹, R², R⁴, R⁵, R⁶ and R⁷ are the same as R^{1'}, R^{2'}, R^{4'}, R^{5'}, R^{6'} and R^{7'}, respectively can be prepared by the following Scheme 3.

5

SCHEME 3

wherein R is an amino protecting group, W is halogen, and R¹, R², R⁴, R⁵, R⁶ and R⁷ are the same as R^{1'}, R^{2'}, R^{4'}, R^{5'}, R^{6'} and R^{7'} respectively and are as described above.

5

As set forth in Scheme 3, a compound of formula XI, a known compound or compound prepared by known methods, is reacted with a compound of formula X, a known compound or compound prepared by known methods, and a base such as methylmagnesium iodide and a base such as sodium hydride in a solvent such as toluene at a temperature of between 25°C and the reflux temperature of the solvent 10 to form a corresponding compound of formula XII.

A compound of formula XII is reacted with a base such as potassium carbonate and an alkylating agent such as CH₃I in a solvent such as N-methylpyrrolidinone at room temperature to form a corresponding compound of 15 formula XIII.

The protecting group R is removed to form a corresponding compound of formula Ia by conventional methods which may include reaction of a compound of formula XIII with potassium hydroxide in a solvent such as ethanol, followed by treatment with a mixture of 1,1,1,3,3-hexa-methyldisilazane and methanol in a 20 solvent such as DMF at room temperature.

A compound of formula I in which one of X and Y signifies O and the other 25 signifies S, is prepared by reacting a compound of formula I in which X and Y both signify O with a sulphurizing agent.

Conventional procedures can be used in carrying out the sulfurization, including the protection of substituents prior to sulfurization and deprotection after 30 sulfurization, which would be known to those skilled in the art.

The sulfurization is conveniently carried out using phosphorous pentasulfide, Lawesson's reagent [2,4-bis(4-methoxyphenyl)-1,2-dithioxo-1,3,2,4-dithiaphosphetane; Bull. Soc. Chim. Belg. 87 (1978) 229-238] or Davy reagent [2,4-bis(methylthio)-1,3,2,4-dithiadiphosphetane; Sulfur Lett. 1983, 1, 167]. This 35

12

reaction is expediently carried out in an inert organic solvent such as an aliphatic or cyclic ether (for example, dimethoxyethane) or an aromatic hydrocarbon which may be halogenated (for example, benzene, toluene or chlorobenzene) and at an elevated temperature, especially at the reflux temperature of the reaction mixture.

5

A compound of formula I in which one of X and Y signifies O and the other signifies (H,OH), is prepared by reducing a compound of formula I in which X and Y both signify O with a complex metal hydride.

10

The reduction can be carried out in a known manner including the protection of substituents on the indole ring prior to reduction and deprotection after reduction according to known methods. An alkali metal aluminum hydride such as lithium aluminum hydride is preferably used as the complex metal hydride, although other hydrides such as diisobutylaluminum hydride and sodium dihydro-bis(2-methoxyethoxy)aluminate can also be used. Suitable inert organic solvents in which this reduction can be carried out include aliphatic and cyclic ethers such as diethyl ether or tetrahydrofuran (THF) and hydrocarbons such as hexane, benzene and toluene. Conveniently, this reduction is carried out at about room temperature.

20

A compound of formula I in which one of X and Y signifies O and the other signifies (H,H), can be prepared by catalytically hydrogenating a compound of formula I in which one of X and Y signifies O and the other signifies (H,OH).

25

Conventional procedures can be used in carrying out the catalytic hydrogenation including the protection and deprotection of substituents on the indole ring according to known procedures. Thus, the catalytic hydrogenation can be carried out in the presence of a noble metal catalyst such as a palladium or platinum catalyst, for example, palladium/carbon (Pd/C), and an inert organic solvent such as an alkanol (for example, methanol or ethanol). This catalytic hydrogenation is expediently carried out at about room temperature and under atmospheric pressure.

30

If desired, an acidic compound of formula I can be converted into a pharmaceutically acceptable salt with a base or a basic compound of formula I can be converted into a pharmaceutically acceptable salt with an acid.

35

The conversion of an acidic compound of formula I into a pharmaceutically acceptable salt can be carried out by treatment with a suitable base in a known manner. Suitable salts are those derived not only from inorganic bases, for example, sodium, potassium or calcium salts, but also from organic bases such as ethylenediamine, monoethanolamine or diethanolamine. The conversion of a basic compound of formula I into a pharmaceutically acceptable salt can be carried out by treatment with a suitable acid in a known manner. Suitable salts are those derived not only from inorganic acids, for example, hydrochlorides, hydrobromides, phosphates or sulphates, but also from organic acids, for example, acetates, citrates, fumarates, tartrates, maleates, methanesulphonates or p-toluenesulphonates.

The pyrroles of formula I and their pharmaceutically acceptable salts inhibit cellular processes, for example cell proliferation, and can be used in the treatment or control of inflammatory disorders such as arthritis, immune diseases, in conjunction with organ transplants and in oncology.

The epithelial breast carcinoma cell line (MDAMB-435) was purchased from ATCC (American Type Cell Culture Collection) and was grown in culture in medium as recommended by ATCC. For analysis of the effect of various compounds on growth of these cells, the cells were plated at a concentration of 1500 cells/well in a 96 well tissue culture plate (test plate). The day after the cells were plated, the compounds to be analyzed were dissolved in 100% DMSO (dimethyl sulfoxide) to yield at 10mM stock solution. Each compound was diluted in H₂O to 1mM and was added to triplicate wells in the first row of a 96 well master plate which contains medium to yield a final concentration of 40µM. The compounds were then serially diluted in medium in the „master plate“. The diluted compound(s) were then transferred to test plates containing cells. A row of vehicle „control cells“ received DMSO. The final concentration of DMSO in each well was 0.1%. 5 days post drug addition, the plate was analyzed as follows:


MTT (3-(4-5 methyl thiazole-2-yl)-2,5-diphenyl tetrazolium bromide; thiazolyl blue) was added to each well to yield a final concentration of 1mg/ml. The plate was then incubated at 37°C for 2 1/2 - 3 hours. The MTT containing medium was then removed and 50µl of 100% ethanol was added to each well to dissolve the formazan. The absorbences were then read using an automated plate reader (Bio-tek microplate

¹⁴

reader). IC₅₀'s were calculated using the Reed and Munsch equation, see Am. J. Hygiene Vol. 27 pgs. 493-497, 1938.

The results are provided in the Table below for compounds of formula Ia.

15
TABLE



Ia

wherein R¹ and R^{1'} are methyl and

5

R ⁴	R ⁵	R ⁶	R ^{6'}	IC ₅₀ (μM)
H	H	OCH ₃	NO ₂	0.007
H	H	CH ₃	OCH ₃	0.02
H	H	CH ₃	NO ₂	0.07
H	H	NO ₂	SCH ₃	0.007
H	H	NO ₂	Obenzyl	0.09
H	H	NO ₂	Cl	0.07
H	H	OCH ₃	OCH ₃	0.005
H	H	NO ₂	F	0.07
H	H	NO ₂	NO ₂	0.07
H	H	F	OCH ₃	0.02
H	H	Cl	OCH ₃	0.007
H	H	CO ₂ CH ₃	NO ₂	0.007
H	H	CN	NO ₂	0.05
H	H	CH ₃	CN	0.01
H	H	CN	OCH ₃	0.005
H	H	CH ₃ S	NO ₂	0.009
H	H	Br	NO ₂	0.07
H	H	N ₃	CH ₃ O	0.07
H	H	Et(OCH ₂ CH ₂)	NO ₂	0.04
H	H	NH ₂	CN	<0.01
H	H	NH ₂	NH ₂	0.7
H	H	NH ₂	F	0.042
H	H	NH ₂	Cl	0.012
H	H	NH ₂	Br	0.004
H	H	NH ₂	CO ₂ CH ₃	0.05
H	H	NH ₂	CH ₃ O	0.015
H	H	NH ₂	EtO	0.012
H	H	NH ₂	NO ₂	<0.01
H	H	CH ₃ CONH	NO ₂	0.02
H	H	CF ₃ CONH	NO ₂	0.012

Continued

R ⁴	R ⁵	R ⁶	R ^{6'}	IC ₅₀ (mM)
H	H	CHONH	CH ₃ O	0.01
H	H	CH ₃ CONH	CH ₃ O	0.07
H	H	CH ₃ NH	CH ₃ O	<0.01
H	CN	H	CH ₃	0.4
H	CH ₃	H	NO ₂	0.13
H	CN	H	NO ₂	1.0
H	Cl	H	NO ₂	0.17
H	NO ₂	H	NO ₂	0.83
H	CH ₃ O	H	CH ₃ O	0.07
H	CH ₃ O	H	CN	0.07
H	CH ₃ O	H	Cl	0.2
H	CH ₃ O	H	CH ₃ S	0.2
H	CH ₃ O	H	EtO	0.07
H	CH ₃	H	CH ₃	0.4
H	Cl	H	CH ₃	0.4
CH ₃ O	H	H	NO ₂	0.4
CH ₃ O	H	H	CH ₃ O	0.07
F	H	H	CH ₃ O	0.2
F	H	H	NO ₂	0.05
F	H	H	EtO	0.032
Br	H	H	EtO	0.2

5 The pyrroles of formula I and their aforementioned salts can be used as medicaments, for example, in the form of pharmaceutical preparations, which can be administered orally, for example, in the form of tablets, coated tablets, dragees, hard or soft gelatin capsules, solutions, emulsions or suspensions. They can also be administered rectally, for example, in the form of suppositories or parenterally, for
10 example, in the form of injection solutions.

For the manufacture of pharmaceutical preparations these compounds can be formulated with therapeutically inert, inorganic or organic carriers. Lactose, maize starch or derivatives thereof, talc, steric acid or its salts can be used as such carriers for tablets, coated tablets, dragees and hard gelatin capsules. Suitable carriers for soft gelatin capsules are vegetable oils, waxes, fats, semi-solid or liquid polyols.
15 Depending on the nature of the active substance no carriers are, however, generally

17

required in the case of soft gelatin capsules. Suitable carriers for the manufacture of solutions and syrups are, water, polyols, saccharose, invert sugar and glucose. Suitable carriers for injection solutions are water, alcohols, polyols, glycerine and vegetable oils. Suitable carriers for suppositories are natural or hardened oils, waxes, fats and semi-liquid polyols.

The pharmaceutical preparations can also contain preserving agents, solubilizing agents, stabilizing agents, wetting agents, emulsifying agents, sweetening agents, coloring agents, flavoring agents, salts for varying the osmotic pressure, buffers, coating agents or antioxidants. They can also contain still other therapeutically valuable substances.

As mentioned above, the pyrroles of formula I and their aforementioned salts can be used in the treatment or control of oncological, inflammatory, immunological, bronchopulmonary and cardiovascular disorders. The dosage can vary within wide limits and will, or course, be adjusted to the individual requirements in each particular case. In general, in the case of oral administration to adult humans, a daily dosage of about 5mg to 5000 mg should be appropriate, although the upper limit may be exceeded when this is found to be expedient. The daily dosage can be administered as a single dose or in divided doses.

The following Examples illustrate the present invention:

EXAMPLE 1

25

3-(6-methoxy-1-methyl-1H-indol-3-yl)-4-(1-methyl-6-nitro-1H-indol-3-yl)-pyrrole-2,5-dione

30

a) A solution of known 6-nitro-1H-indole (5g, 31mM) in dimethylformamide (DMF) (50ml) was cooled to 0°C and treated with NaH (1g, 37m). After stirring at 0°C for two hours, CH₃I (2.3ml, 37 mM) was added, and the reaction was stirred overnight while allowing to warm to room temperature. After pouring into H₂O (500ml), the mixture was extracted with ethyl acetate (EtOAc, 200ml x 4). The combined organic fractions were dried over MgSO₄,

filtered and evaporated. Purification by flash column chromatography afforded the 1-methyl-6-nitro-1H-indole (5.34 g, 97%).

- 5 b) A stirred solution of 1-methyl-6-nitro-1H-indole in diethyl ether (Et_2O , 5ml) was cooled to 0°C, and treated with oxalyl chloride (0.15 ml, 1.7mM). After stirring at room temperature overnight, solids were collected, washed with ether and dried to afford (255 mg, 96%) (1-methyl-6-nitro-1H-indol-3-yl)-oxo-acetyl chloride.
- 10 c) A mixture of DMF (7ml, 90mM) and POCl_3 (2.25ml, 24.5mMol) which had been cooled to 5°C, was treated with known 6-methoxy-1H-indole. After stirring at room temperature for 1 hour, the mixture was heated at 45°C for 1 hour, then allowed to cool to room temperature overnight. The reaction mixture was poured into ice (100ml), and stirred for 30 minutes at which time a solution of KOH (9.6g, 171mM) in H_2O (20ml) was added dropwise. After stirring for 30 minutes, then heating for 1 hour at 60°C, the reaction was cooled to 30°C, and the pH adjusted to 7 with 1N HCl. The mixture was extracted with EtOAc(50ml x 3), the organic fractions were combined, dried over MgSO_4 , filtered and evaporated. The residue was purified by crystallization from methanol to afford 6-methoxy-1H-indole-3-carboxaldehyde (1.65g, 69%).
- 15 d) A solution of 6-methoxy-1H-indole-3-carboxaldehyde (1.65, 9.4mmM in DMF (10ml) was cooled to 0°C, and treated with NaH (11.3mM). After stirring at room temperature for 1 hour, the mixture was cooled to 0°C, treated with CH_3I (.7ml, 11.3mM), then allowed to warm to room temperature overnight. After pouring into H_2O (200ml), the mixture was acidified with HCl and extracted with EtOAc (100ml x 2). The combined organic fractions were dried over MgSO_4 , filtered and evaporated to afford 6-methoxy-1-methyl-1H-indole-3-carboxaldehyde (1.78g, 99%).
- 20 e) To a cooled (-30°C) suspension of potassium tert-butoxide (KOtBu , 1.62g, 14.4mM) in dimethoxyethane (DME; 25ml) was added a solution of toluene-4-sulfonylmethyl isocyanide (TosMIC, 1.45 g, 7.4mM) in DME (15ml). After cooling the mixture further to -60°C, a solution of 6-methoxy-1-
- 25
- 30
- 35

-19

methyl-1H-indole-3-carboxaldehyde (800 mg, 4.23 mM) was slowly added, and the reaction mixture stirred for 1.5 hours. After treatment with methanol (11ml), the mixture was heated to reflux temperature for 15 minutes, then the solvent evaporated. The residue was treated with H₂O (15ml) which contained acetic acid (HOAc, 55ml), then extracted with CH₂Cl₂ (50ml x 3). The combined organic layers were washed with saturated NaHCO₃ solution (50ml), dried over MgSO₄, filtered and evaporated. Purification by flash column chromatography afforded (6-methoxy-1-methyl-1H-indol-3-yl)-acetonitrile (0.6g, 70%).

10

f) HCl gas was bubbled into a suspension of (6-methoxy-1-methyl-1H-indol-3-yl)-acetonitrile in isopropanol (25ml) which was cooled to 0°C. After 3 hours, the solvent was evaporated and the residue evaporated from diethyl ether (Et₂O, 50ml x 2). The tan residue was further dried under high vacuum to afford 2-(6-methoxy-1-methyl-1H-indol-3-yl)-acetimidic acid isopropyl ester hydrochloride (1.6g, 82%).

15

g) A suspension of (1-methyl-6-nitro-1H-indol-3-yl)-oxo-acetyl chloride (251mg, 0.94mM) and 2-(6-methoxy-1-methyl-1H-indol-3-yl)-acetimidic acid isopropyl ester hydrochloride (280mg, 0.94 mM) in CH₂Cl₂ (25ml) was cooled to 0°C, treated with Et₃N (0.53ml, 3.7mM), and stirred at room temperature while allowing to warm to room temperature overnight. The mixture was then diluted with CH₂Cl₂ (25ml), washed with H₂O (20ml), and 0.5 N HCl (20ml). The combined organic layers were dried over MgSO₄, filtered and evaporated. The residue was then combined with toluene (4ml), cooled to 0°C, treated with pTsOH (197mg, 1mM), and stirred for 3 hours. The red solids which precipitated were collected and partitioned between CH₂Cl₂ (50ml), and H₂O (25ml). The organic fraction was washed with saturated NaHCO₃ solution (25ml), then dried over MgSO₄, filtered and evaporated. Rinsing the residue with tetrahydrofuran (THF) afforded 3-(6-methoxy-1-methyl-1H-indol-3-yl)-4-(1-methyl-6-nitro-1H-indol-3yl)-pyrrole-2,5-dione, mp 308-310°C, in 31% yield.

20

25

30

20
EXAMPLE 2

In a manner similar to that described in Example 1g), the following compounds were prepared. The starting materials were prepared in a manner 5 analogous to that described in 1b) and 1f).

- a) 3-(6-Benzyl-1-methyl-1H-indol-3-yl)-4-(1-methyl-6-nitro-1H-indol-3-yl)-pyrrole-2,5-dione, mp 160-165°C, was prepared from (6-benzyl-1-methyl-1H-indol-3-yl)-oxo-acetyl chloride and 2-(1-methyl-6-nitro-1H-indol-3-yl)-acetimidic acid isopropyl ester hydrochloride.
- b) 3-(6-Chloro-1-methyl-1H-indol-3-yl)-4-(1-methyl-6-nitro-1H-indol-3-yl)-pyrrole-2,5-dione, mp 300-302°C, was prepared from (6-chloro-1-methyl-1H-indol-3-yl)-oxo-acetyl chloride and 2-(1-methyl-6-nitro-1H-indol-3-yl)-acetimidic acid isopropyl ester hydrochloride.
- c) 3-(1,6-Dimethyl-1H-indol-3-yl)-4-(6-methoxy-1-methyl-1H-indol-3-yl)-pyrrole-2,5-dione, mp 240-245°C, was prepared from (6-methoxy-1-methyl-1H-indol-3-yl)-oxo-acetyl chloride and 2-(1,6-dimethyl-1H-indol-3-yl)-acetimidic acid isopropyl ester hydrochloride.
- d) 3-(1,6-Dimethyl-1H-indol-3-yl)-4-(1-methyl-6-nitro-1H-indol-3-yl)-pyrrole-2,5-dione, mp 268-272°C, was prepared from (1-methyl-6-nitro-1H-indol-3-yl)-oxo-acetyl chloride and 2-(1,6-dimethyl-1H-indol-3-yl)-acetimidic acid isopropyl ester hydrochloride.
- e) 3,4-Bis-(6-methoxy-1-methyl-1H-indol-3-yl)-pyrrole-2,5-dione, mp 258-260°C, was prepared from (6-methoxy-1-methyl-1H-indol-3-yl)-oxo-acetyl chloride and 2-(6-methoxy-1-methyl-1H-indol-3-yl)-acetimidic acid isopropyl ester hydrochloride.
- f) 3-(6-Fluoro-1-methyl-1H-indol-3-yl)-4-(1-methyl-6-nitro-1H-indol-3-yl)-pyrrole-2,5-dione, mp 270-272°C, was prepared from (6-fluoro-1-methyl-1H-indol-3-yl)-oxo-acetyl chloride and 2-(1-methyl-6-nitro-1H-indol-3-yl)-acetimidic acid isopropyl ester hydrochloride.

- g) 3,4-Bis-(1-methyl-6-nitro-1H-indol-3-yl)-pyrrole-2,5-dione, mp >360°C,
was prepared from (1-methyl-6-nitro-1H-indol-3-yl)-oxo-acetyl chloride and
2-(1-methyl-6-nitro-1H-indol-3-yl)-acetimidic acid isopropyl ester
hydrochloride.
- 5
- h) 3-(6-Fluoro-1-methyl-1H-indol-3-yl)-4-(6-methoxy-1-methyl-1H-indol-3-
yl)-pyrrole-2,5-dione, mp 255-257°C, was prepared from (6-fluoro-1-
methyl-1H-indol-3-yl)-oxo-acetyl chloride and 2-(6-methoxy-1-methyl-1H-
10 indol-3-yl)-acetimidic acid isopropyl ester hydrochloride.
- i) 3-(6-Chloro-1-methyl-1H-indol-3-yl)-4-(6-methoxy-1-methyl-1H-indol-3-
yl)-pyrrole-2,5-dione, mp 283-285°C, was prepared from (6-chloro-1-
methyl-1H-indol-3-yl)-oxo-acetyl chloride and 2-(6-methoxy-1-methyl-1H-
15 indol-3-yl)-acetimidic acid isopropyl ester hydrochloride.
- j) 1-Methyl-3-[4-(1-methyl-6-nitro-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-
pyrrole-3-yl]-1H-indole-6-carboxylic acid methyl ester, mp 294-296°C, was
prepared from (1-methyl-6-methoxycarbonyl-1H-indol-3-yl)-oxo-acetyl
20 chloride and 2-(1-methyl-6-nitro-1H-indol-3-yl)-acetimidic acid isopropyl
ester hydrochloride.
- k) 1-Methyl-3-[4-(1-methyl-6-nitro-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-
pyrrol-3-yl]-1H-indole-6-carbonitrile, mp 253-255°C(dec.), was prepared
25 from (6-cyano-1-methyl-1H-indol-3-yl)-oxo-acetyl chloride and 2-(1-methyl-
6-nitro-1H-indol-3-yl)-acetimidic acid isopropyl ester hydrochloride.
- l) 3-[4-(1,6-Dimethyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrole-3-yl]-
1-methyl-1H-indole-6- carbonitrile, mp 310-312°C, was prepared from (6-
30 cyano-1-methyl-1H-indol-3-yl)-oxo-acetyl chloride and 2-(1,6-dimethyl-1H-
indol-3-yl)-acetimidic acid isopropyl ester hydrochloride.
- m) 3-[4-(6-Methoxy-1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-
pyrrole-3-yl]-1-methyl-indol-6- carbonitrile, mp 261-263°C, was prepared
35 from (6-cyano-1-methyl-1H-indol-3-yl)-oxo-acetyl chloride and 2-(6-

22

methoxy-1-methyl-1H-indol-3-yl)-acetimidic acid isopropyl ester hydrochloride.

- n) 3-(1-Methyl-6-methylsulfanyl-1H-indol-3-yl)-4-(1-methyl-6-nitro-1H-indol-3-yl)-pyrrole-2,5-dione, mp 273-275°C, was prepared from (1-methyl-6-methylsulfanyl-1H-indol-3-yl)-oxo-acetyl chloride and 2-(1-methyl-6-nitro-1H-indol-3-yl)-acetimidic acid isopropyl ester hydrochloride.
- o) 3-(6-Bromo-1-methyl-1H-indol-3-yl)-4-(1-methyl-6-nitro-1H-indol-3-yl)-pyrrole-2,5-dione, mp 319-321°C, was prepared from (6-bromo-1-methyl-1H-indol-3-yl)-oxo-acetyl chloride and 2-(1-methyl-6-nitro-1H-indol-3-yl)-acetimidic acid isopropyl ester hydrochloride.
- p) 3-(6-Iodo-1-methyl-1H-indol-3-yl)-4-(1-methyl-6-nitro-1H-indol-3-yl)-pyrrole-2,5-dione, mp 317-321°C, was prepared from (6-iodo-1-methyl-1H-indol-3-yl)-oxo-acetyl chloride and 2-(1-methyl-6-nitro-1H-indol-3-yl)-acetimidic acid isopropyl ester hydrochloride.
- q) 3-(6-Azido-1-methyl-1H-indol-3-yl)-4-(6-methoxy-1-methyl-1H-indol-3-yl)-pyrrole-2,5-dione was prepared from (6-azido-1-methyl-1H-indol-3-yl)-oxo-acetyl chloride and 2-(6-methoxy-1-methyl-1H-indol-3-yl)-acetimidic acid isopropyl ester hydrochloride.
- r) 3-(4-Methoxy-1-methyl-1H-indol-3-yl)-4-(1-methyl-6-nitro-1H-indol-3-yl)-pyrrole-2,5-dione, mp 290-292°C, was prepared from (4-methoxy-1-methyl-1H-indol-3-yl)-oxo-acetyl chloride and 2-(1-methyl-6-nitro-1H-indol-3-yl)-acetimidic acid isopropyl ester hydrochloride.
- s) 3-(6-Methoxy-1-methyl-1H-indol-3-yl)-4-(4-methoxy-1-methyl-1H-indol-3-yl)-pyrrole-2,5-dione, mp 270-273°C, was prepared from (4-methoxy-1-methyl-1H-indol-3-yl)-oxo-acetyl chloride and 2-(6-methoxy-1-methyl-1H-indol-3-yl)-acetimidic acid isopropyl ester hydrochloride.
- t) 3-(4-Fluoro-1-methyl-1H-indol-3-yl)-4-(6-methoxy-1-methyl-1H-indol-3-yl)-pyrrole-2,5-dione, mp 283-285°C, was prepared from (4-fluoro-1-

methyl-1H-indol-3-yl)-oxo-acetyl chloride and 2-(6-methoxy-1-methyl-1H-indol-3-yl)-acetimidic acid isopropyl ester hydrochloride.

- 5 u) 3-(4-Fluoro-1-methyl-1H-indol-3-yl)-4-(1-methyl-6-nitro-1H-indol-3-yl)-
 pyrrole-2,5-dione was prepared from (4-fluoro-1-methyl-1H-indol-3-yl)-oxo-
 acetyl chloride and 2-(1-methyl-6-nitro-1H-indol-3-yl)-acetimidic acid
 isopropyl ester hydrochloride.
- 10 v) 3-[4-(5-Methoxy-1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-
 pyrrol-3-yl]-1-methyl-1H-indole-6-carbonitrile, mp 326-328°C, was
 prepared from (6-cyano-1-methyl-1H-indol-3-yl)-oxo-acetyl chloride and 2-(5-methoxy-1-methyl-1H-indol-3-yl)-acetimidic acid isopropyl ester
 hydrochloride.
- 15 w) 3-(6-Chloro-1-methyl-1H-indol-3-yl)-4-(5-methoxy-1-methyl-1H-indol-3-
 yl)-pyrrole-2,5-dione, mp 289-292°C, was prepared from (6-chloro-1-
 methyl-1H-indol-3-yl)-oxo-acetyl chloride and 2-(5-methoxy-1-methyl-1H-
 indol-3-yl)-acetimidic acid isopropyl ester hydrochloride.
- 20 x) 3-(5-Methoxy-1-methyl-1H-indol-3-yl)-4-(1-methyl-6-methylsulfanyl-1H-
 indol-3-yl)-pyrrole-2,5-dione, mp 261-264°C, was prepared from (1-methyl-
 6-methylsulfanyl-1H-indol-3-yl)-oxo-acetyl chloride and 2-(5-methoxy-1-
 methyl-1H-indol-3-yl)-acetimidic acid isopropyl ester hydrochloride.
- 25 y) 3-(6-Ethoxy-1-methyl-1H-indol-3-yl)-4-(5-methoxy-1-methyl-1H-indol-3-
 yl)-pyrrole-2,5-dione, mp 229-232°C, was prepared from (6-ethoxy-1-
 methyl-1H-indol-3-yl)-oxo-acetyl chloride and 2-(5-methoxy-1-methyl-1H-
 indol-3-yl)-acetimidic acid isopropyl ester hydrochloride.
- 30 z) 3-(1,6-Dimethyl-1H-indol-3-yl)-4-(1,5-dimethyl-1H-indol-3-yl)-pyrrole-2,5-
 dione, mp 248-250°C, was prepared from (1,6-dimethyl-1H-indol-3-yl)-oxo-
 acetyl chloride and 2-(1,5-dimethyl-1H-indol-3-yl)-acetimidic acid isopropyl
 ester hydrochloride.

24

- aa) 3-(5-Chloro-1-methyl-1H-indol-3-yl)-4-(1,6-dimethyl-1H-indol-3-yl)-pyrrole-2,5-dione, mp 247-249°C, was prepared from (5-chloro-1-methyl-1H-indol-3-yl)-oxo-acetyl chloride and 2-(1,6-dimethyl-1H-indol-3-yl)-acetimidic acid isopropyl ester hydrochloride.
- bb) 3-[4-(1,6-Dimethyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1-methyl-1H-indole-5-carbonitrile, mp 269-271°C, was prepared from (5-cyano-1-methyl-1H-indol-3-yl)-oxo-acetyl chloride and 2-(1,6-dimethyl-1H-indol-3-yl)-acetimidic acid isopropyl ester hydrochloride.
- cc) 3-(1,5-Dimethyl-1H-indol-3-yl)-4-(1-methyl-6-nitro-1H-indol-3-yl)-pyrrole-2,5-dione, mp 248-250°C, was prepared from (1,5-dimethyl-1H-indol-3-yl)-oxo-acetyl chloride and 2-(1-methyl-6-nitro-1H-indol-3-yl)-acetimidic acid isopropyl ester hydrochloride.
- dd) 1-Methyl-3-[4-(1-methyl-6-nitro-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indole-5-carbonitrile, mp 257-260°C, was prepared from (5-cyano-1-methyl-1H-indol-3-yl)-oxo-acetyl chloride and 2-(1-methyl-6-nitro-1H-indol-3-yl)-acetimidic acid isopropyl ester hydrochloride.
- ee) 3-(5-Chloro-1-methyl-1H-indol-3-yl)-4-(1-methyl-6-nitro-1H-indol-3-yl)-pyrrole-2,5-dione, mp 301-303°C, was prepared from (5-chloro-1-methyl-1H-indol-3-yl)-oxo-acetyl chloride and 2-(1-methyl-6-nitro-1H-indol-3-yl)-acetimidic acid isopropyl ester hydrochloride.
- ff) 3-(1-Methyl-5-nitro-1H-indol-3-yl)-4-(1-methyl-6-nitro-1H-indol-3-yl)-pyrrole-2,5-dione, mp 270°C, was prepared from (1-methyl-5-nitro-1H-indol-3-yl)-oxo-acetyl chloride and 2-(1-methyl-6-nitro-1H-indol-3-yl)-acetimidic acid isopropyl ester hydrochloride.
- gg) 3-(5-Methoxy-1-methyl-1H-indol-3-yl)-4-(4-methoxy-1-methyl-1H-indol-3-yl)-pyrrole-2,5-dione, mp 250-254°C, was prepared from (4 -methoxy-1-methyl-1H-indol-3-yl)-oxo-acetyl chloride and 2-(5-methoxy-1-methyl-1H-indol-3-yl)-acetimidic acid isopropyl ester hydrochloride.

35

25

- hh) 3,4-Bis-(5-methoxy-1-methyl-1H-indol-3-yl)-pyrrole-2,5-dione, mp 236-238°C, was prepared from (5-methoxy-1-methyl-1H-indol-3-yl)-oxo-acetyl chloride and 2-(5-methoxy-1-methyl-1H-indol-3-yl)-acetimidic acid isopropyl ester hydrochloride.
- 5 ii) 3-(1,5-Dimethyl-1H-indol-3-yl)-4-(5-methoxy-1-methyl-1H-indol-3-yl)-pyrrole-2,5-dione, mp 217-220°C, was prepared from (1,5-dimethyl-1H-indol-3-yl)-oxo-acetyl chloride and 2-(5-methoxy-1-methyl-1H-indol-3-yl)-acetimidic acid isopropyl ester hydrochloride.
- 10 jj) 3-(5-Chloro-1-methyl-1H-indol-3-yl)-4-(5-methoxy-1-methyl-1H-indol-3-yl)-pyrrole-2,5-dione, mp 245-248°C, was prepared from (5-chloro-1-methyl-1H-indol-3-yl)-oxo-acetyl chloride and 2-(5-methoxy-1-methyl-1H-indol-3-yl)-acetimidic acid isopropyl ester hydrochloride.
- 15 kk) 3-[4-(5-Methoxy-1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1-methyl-1H-indole-5-carbonitrile, mp 252-255°C, was prepared from (5-cyano-1-methyl-1H-indol-3-yl)-oxo-acetyl chloride and 2-(5-methoxy-1-methyl-1H-indol-3-yl)-acetimidic acid isopropyl ester hydrochloride.
- 20 ll) 3-(1-Methyl-6-nitro-1H-indol-3-yl)-4-(1-methyl-7-nitro-1H-indol-3-yl)-pyrrole-2,5-dione was prepared from (1-methyl-6-nitro-1H-indol-3-yl)-oxo-acetyl chloride and 2-(1-methyl-7-nitro-1H-indol-3-yl)-acetimidic acid isopropyl ester hydrochloride.
- 25 mm) 3-(6-Fluoro-1-methyl-1H-indol-3-yl)-4-(1-methyl-7-nitro-1H-indol-3-yl)-pyrrole-2,5-dione was prepared from (6-fluoro-1-methyl-1H-indol-3-yl)-oxo-acetyl chloride and 2-(1-methyl-7-nitro-1H-indol-3-yl)-acetimidic acid isopropyl ester hydrochloride.
- 30 nn) 3-(1,6-Dimethyl-1H-indol-3-yl)-4-(1-methyl-7-nitro-1H-indol-3-yl)-pyrrole-2,5-dione, mp 259-261°C, was prepared from (1-methyl-7-nitro-1H-indol-3-yl)-oxo-acetyl chloride and 2-(1,6-dimethyl-1H-indol-3-yl)-acetimidic acid isopropyl ester hydrochloride.

26

- oo) 3-(4-Fluoro-1-methyl-1H-indol-3-yl)-4-(6-ethoxy-1-methyl-1H-indol-3-yl)-pyrrole-2,5-dione, mp >280°C, was prepared from (4-fluoro-1-methyl-1H-indol-3-yl)-oxo-acetyl chloride and 2-(6-ethoxy-1-methyl-1H-indol-3-yl)-acetimidic acid isopropyl ester hydrochloride.
- 5 pp) 3-(4-Bromo-1-methyl-1H-indol-3-yl)-4-(6-ethoxy-1-methyl-1H-indol-3-yl)-pyrrole-2,5-dione, mp >266°C, was prepared from (4-bromo-1-methyl-1H-indol-3-yl)-oxo-acetyl chloride and 2-(6-ethoxy-1-methyl-1H-indol-3-yl)-acetimidic acid isopropyl ester hydrochloride.
- 10 qq) 3-(6-Ethoxy-1-methyl-1H-indol-3-yl)-4-(1-methyl-6-nitro-1H-indol-3-yl)-pyrrole-2,5-dione, mp 260°C, was prepared from (1-methyl-6-nitro-1H-indol-3-yl)-oxo-acetyl chloride and 2-(6-ethoxy-1-methyl-1H-indol-3-yl)-acetimidic acid isopropyl ester hydrochloride.
- 15 rr) 3-{6-[2-(2-Ethoxy-ethoxy)-ethoxy]-1-methyl-1H-indol-3-yl}-4-(1-methyl-6-nitro-1H-indol-3-yl)-pyrrole-2,5-dione, mp 124°C, was prepared from {6-[2-(2-ethoxy-ethoxy)-ethoxy]-1-methyl-1H-indol-3-yl}-oxo-acetyl chloride and 2-(1-methyl-6-nitro-1H-indol-3-yl)-acetimidic acid isopropyl ester hydrochloride.
- 20 ss) N-{1-Methyl-3-[4-(1-methyl-6-nitro-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-3-yl}-acetamide was prepared from (6-acetylamino-1-methyl-1H-indol-3-yl)-oxo-acetyl chloride and 2-(1-methyl-6-nitro-1H-indol-3-yl)-acetimidic acid isopropyl ester hydrochloride.
- 25

EXAMPLE 3

- 30 3-(1-methyl-6-methylsulfanyl-1H-indol-3-yl)-4-(1-methyl-6-nitro-1H-indol-3-yl)-pyrrole-2,5-dione
- a) To a solution of sodium methoxide prepared from Na metal (8.65 g, 0.38M) in methanol (200ml) at 0-5°C, was added a solution of 4-(methylthio)-benzaldehyde (12.6 ml, 94.7mM) and methyl azidoacetate (44 g, 0.382M) in
- 35

27

methanol (30ml). After stirring at the same temperature for 3 hours, the suspension was diluted with H₂O (300ml). The solids were filtered, washed with water and dried under vacuum to provide 19.4 g (82.0%) of methyl-2-azido-3-(4-methylthio-phenyl)-propenoate as a yellow solid.

5

A solution of methyl-2-azido-3-(4-methylthiophenyl)-propenoate (20.6g, 83mM) in xylene (200ml) was added dropwise to boiling xylene (250ml) over a period of 2 hours. The reaction mixture was allowed to heat at reflux temperature for an additional 2 hours, then cooled slowly and placed in a freezer overnight. The solids were filtered, washed with a small amount of CH₂Cl₂/hexane (1:3) and dried to give 11.2g (61.0%) of methyl-6-methylsulfanyl-1H-indole-2-carboxylate.

10

A mixture of methyl-6-methylsulfanyl-1H-indole-2-carboxylate (11.2g, 51mM) and 2N NaOH (125 ml) was heated to reflux temperature for 30 minutes. The clear solution was cooled, and extracted with EtOAc. The aqueous fraction was acidified with concentrated HCl to pH = 1, and the precipitate which formed, was filtered and dried to give 6-methylsulfanyl-1H-indole-2-carboxylic acid (9.6g, 91.0%).

15

A mixture of 6-methylsulfanyl-1H-indole-2-carboxylic acid (9.6g, 46mMol), Cu powder (2.1 g, 33 mM) and quinoline (100 ml) was heated at 215°C for 3 hours. The mixture was cooled to room temperature, filtered through celite, and filtrate diluted with H₂O (500ml). The cooled mixture was acidified with concentrated HCl (pH=1) and extracted with EtOAc. The organic fraction was washed with saturated NaCl solution, dried over MgSO₄, filtered and evaporated to give 6-methyl-sulfanyl-1H-indole (6.8g, 90%) after purification by flash column chromatography.

20

25 b) In a manner similar to that of Example 1f), 2-(1-methyl-6-nitro-1H-indol-3-yl)-acetimidic acid isopropyl ester hydrochloride was prepared from (1-methyl-6-nitro-1H-indol-3-yl)-acetonitrile.

30

28

- 5 c) In a manner similar to that of Example 1g), 3-(1-methyl-6-methylsulfanyl-1H-indol-3-yl)-4-(1-methyl-6-nitro-1H-indol-3-yl)-pyrrole-2,5-dione, mp 273-275°C, was prepared from (1-methyl-6-methylsulfanyl-1H-indol-3-yl)-oxo-acetyl chloride and 2-(1-methyl-6-nitro-1H-indol-3-yl)-acetimidic acid isopropyl ester hydrochloride.

EXAMPLE 4

3,4-Bis-(6-methoxy-1-methyl-indol-3-yl)-pyrrole-2,5-dione

10

- a) A solution of CH_3MgI (15mM, in Et_2O) was treated with a solution of 6-methoxy-1H-indole (2.21 g, 15 mM) in toluene (20ml). After stirring at room temperature for 3.5 hours, a solution of 3,4-dichloro-1-methylmaleimide (1.2g, 6.5 mM) in toluene (20ml) was added dropwise to the suspension.

15

After heating at reflux temperature for 2 hours, the mixture was cooled to room temperature, and treated with NaH (26 mM). After heating the mixture at reflux temperature for 15 hours, the mixture was poured into 20% aqueous citric acid solution and extracted with EtOAc (100ml x 3). The combined organic fractions were washed with H_2O , saturated NaCl solution, and dried over MgSO_4 . After filtration, and evaporation of the solvent, the residue was purified by flash column chromatography to afford 3,4-bis-(6-methoxy-1H-indol-3-yl)-1-methyl maleimide (3.65g, 70%).

20

- b) A solution of 3,4-bis-(6-methoxy-1H-indol-3-yl)-1-methylmaleimide (0.97g, 24mMol) and N-methyl pyrrolidinone (25ml) was treated with K_2CO_3 (5.8g, 42 mMol), and CH_3I (2.13 g, 15 mM). After stirring for 15 hours, volatile liquids were removed, and the product precipitated by addition of H_2O (50ml), collected and washed with H_2O (20ml) and hexane (10ml) to afford 3,4-bis-(6-methoxy-1-methyl-indol-3-yl)-1-methylmaleimide (1g, 96%).

30

- c) A suspension of 3,4-bis-(6-methoxy-1-methyl-indol-3-yl)-1-methylmaleimide (0.96g, 2.23mM) in ethanol (30ml) was treated with 5N KOH (30ml) and heated to reflux temperature until tlc indicated the disappearance of starting material (approximately 22 hours). After removal of most of the ethanol, the pH of the solution was adjusted to 2 by addition

35

29

of 2N HCl. Solids were collected by filtrations and washed with H₂O. This material (0.92g) in DMF (16ml) was treated with pre-mixed solution of 1,1,1,3,3-hexamethyldisilazane (4g, 25mM) and CH₃OH (4g, 12.5 mMol). After stirring the solution for 15 hours at room temperature, H₂O (20 ml) was added and the solids which precipitated were collected by filtration and further washed with H₂O to afford 3,4-bis-(6-methoxy-1-methyl-indol-3-yl)-pyrrole-2,5-dione, mp >350°C.

EXAMPLE 5

10

The following three procedures exemplify methodology to reduce nitro bis-indolymaleimides to amino bis-indolymaleimides.

15

a) 3-[4-(6-Amino-1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1-methyl-1H-indole-6-carbonitrile

20

3-(6-Cyano-1-methyl-1H-indol-3-yl)-4-(1-methyl-6-nitro-1H-indol-3-yl)-pyrrole-2,5-dione (9.0g, 21 mM) was suspended in ethanol (1.8 l) and treated with tin (II) chloride dihydrate (35g, 156 mM). This was mechanically stirred for 16 h at reflux. The reaction was cooled and reduced in volume to 1 liter. This was poured into a mixture of ethyl acetate (2 liters) and saturated sodium bicarbonate solution (1 liter) and well mixed. The organic layer was decanted and washed with saturated sodium bicarbonate solution, dried over magnesium sulfate, filtered, evaporated, and then purified by flash column chromatography (ethyl acetate). The product was further purified by crystallization from tetrahydrofuran/hexane to provide 6.5g of 3-[4-(6-amino-1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1-methyl-1H-indole-6-carbonitrile; mp 255-260°C.

25

b) 3,4-Bis-(6-amino-1H-indol-3-yl)-pyrrole-2,5-dione

30

3,4-Bis-(1-methyl-6-nitro-1H-indol-3-yl)-pyrrole-2,5-dione (50 mg, 0.11 mM), as prepared in Example 2g, was dissolved in N,N-dimethylformamide (10 ml), a catalytic amount of activated Raney Nickel was added and the reaction was shaken on a Parr Hydrogenator at 45 psi. for 20 hr. The reaction mixture was filtered through a bed of celite with ethyl acetate and concentrated. The product was

35

30

purified by recrystallization from acetone and hexane to give 3,4-bis-(1-methyl-6-amino-1H-indol-3-yl)-pyrrole-2,5-dione (35 mg).

- 5 c) 3-(6-Amino-1-methyl-1H-indol-3-yl)-4-(6-fluoro-1-methyl-1H-indol-3-yl)-
 pyrrole-2,5-dione

To a suspension of 1.0 g (2.39 mMole) of 3-(6-fluoro-1-methyl-1H-indol-3-yl)-4-(1-methyl-6-nitro-1H-indol-3-yl)-pyrrole-2,5-dione in 20 ml of ethanol and 10 ml of tetrahydrofuran was added 0.55 g of 10% Pd/C and 0.54 ml of 5% hydrochloric acid. The mixture was cooled in an ice bath, and 0.54 ml (14.34 mM) of hydrazine hydrate (85%) was added dropwise over 5 min. The reaction mixture was allowed to warm to room temp as it was stirred for two hours. The catalyst was removed by filtration over Celite. The filtrate was evaporated and the residue was crystallized from ethyl acetate/ tetrahydrofuran/ hexane to give 708 mg (76%) of 15
3-(6-amino-1-methyl-1H-indol-3-yl)-4-(6-fluoro-1-methyl-1H-indol-3-yl)-pyrrole-2,5-dione.

EXAMPLE 6

20 Following the indicated general procedure outlined in Example 5, the following compounds were prepared:

- a) 3-(6-Amino-1-methyl-1H-indol-3-yl)-4-(6-chloro-1-methyl-1H-indol-3-yl)-
 pyrrole-2,5-dione was prepared from 3-(6-chloro-1-methyl-1H-indol-3-yl)-4-(1-
 methyl-6-nitro-1H-indol-3-yl)-pyrrole-2,5-dione utilizing procedure c) in Example 5.
25
b) 3-(6-Amino-1-methyl-1H-indol-3-yl)-4-(6-bromo-1-methyl-1H-indol-3-yl)-
 pyrrole-2,5-dione was prepared from 3-(6-bromo-1-methyl-1H-indol-3-yl)-4-(1-
 methyl-6-nitro-1H-indol-3-yl)-pyrrole-2,5-dione utilizing procedure a) in Example 5.
30
c) 3-[4-(6-Amino-1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1-methyl-1H-indole-6-carboxylic acid methyl ester was prepared from 3-[4-(1-methyl-6-nitro-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1-methyl-1H-indole-6-carboxylic acid methyl ester utilizing procedure a) in Example 5.

31

- d) 3-(6-Amino-1-methyl-1H-indol-3-yl)-4-(1-methyl-6-methylsulfanyl-1H-indol-3-yl)-pyrrole-2,5-dione was prepared from 3-(1-methyl-6-methylsulfanyl-1H-indol-3-yl)-4-(1-methyl-6-nitro-1H-indol-3-yl)-pyrrole-2,5-dione utilizing procedure a) in Example 5.
- 5 e) 3-(6-Amino-1-methyl-1H-indol-3-yl)-4-(1,6-dimethyl-1H-indol-3-yl)-pyrrole-2,5-dione was prepared from 3-(1,6-dimethyl-1H-indol-3-yl)-4-(1-methyl-6-nitro-1H-indol-3-yl)-pyrrole-2,5-dione utilizing procedure c) in Example 5.
- 10 f) 3-(6-Amino-1-methyl-1H-indol-3-yl)-4-(6-methoxy-1-methyl-1H-indol-3-yl)-pyrrole-2,5-dione was prepared from 3-(6-methoxy-1-methyl-1H-indol-3-yl)-4-(1-methyl-6-nitro-1H-indol-3-yl)-pyrrole-2,5-dione utilizing procedure b) in Example 5.

15

EXAMPLE 7

General procedure for preparing hydrochloride salts of amino bis indolymaleimides:

20 3-(6-Amino-1-methyl-1H-indol-3-yl)-4-(6-fluoro-1-methyl-1H-indol-3-yl)-pyrrole-2,5-dione hydrochloride salt

25 To a mixture of 75 mg (0.193 mM) of 3-(6-amino-1-methyl-1H-indol-3-yl)-4-(6-fluoro-1-methyl-1H-indol-3-yl)-pyrrole-2,5-dione in 2 ml of acetonitrile were added 10 ml of water, precipitating solids. To this mixture was added 0.64 ml (0.772 mM) of 1.2M hydrochloric acid, forming a clear solution. After 10 min. the mixture was concentrated to dryness. It was redissolved in acetonitrile and concentrated to dryness. The residue was dissolved in 4 ml of water and lyophilized overnight to give 80 mg (97%) of 3-(6-amino-1-methyl-1H-indol-3-yl)-4-(6-fluoro-1-methyl-1H-indol-3-yl)-pyrrole-2,5-dione hydrochloride salt.

30

In a similar manner, the hydrochloride salts of other amines were prepared.

EXAMPLE 8

3-(6-Amino-1-methyl-1H-indol-3-yl)-4-(1-methyl-6-nitro-1H-indol-3-yl)-pyrrole-2,5-dione

5

a) 5.29 g of 1-methyl-6-nitroindole and 7.5 g 10 % Pd/C in 400 ml ethanol was treated with 30 ml 2N hydrochloric acid and 2.04 ml 85% hydrazine hydrate at 0°C. It was stirred at room temperature and treated portionwise with 1 ml hydrazine hydrate. The mixture was filtered over a bed of celite and washed with ethanol. The filtrate was concentrated to 50 ml and cooled to 0°C for 1 h. Fine needle crystals were filtered off as hydrazine hydro-chloride. The filtrate was concentrated to 25 ml, refrigerated and filtered to remove more by-product. The filtrate was treated portionwise with cold 6N hydrochloric acid and concentrated to about 25 ml, refrigerated and tan crystals of product collected. The filtrate was again concentrated to about 10 ml and again treated with cold 6N hydrochloric acid, concentrated and redissolved in 5 ml of ethanol and hexane to further crystallize product. The tan crystals were collected and the combined yield was 2.80 g of 6-amino-1-methylindole hydrochloride.

10

15

20

25

30

35

b) 2.5 g of 6-amino-1-methylindole hydrochloride was taken into 30 ml of dry pyridine and treated with 1.93 ml of trifluoroacetic anhydride at 0°C. It was stored in the refrigerator overnight. It was taken into cold water and extracted with ethyl acetate and washed with cold 5% phosphoric acid and 5% brine. The organic extracts were dried over magnesium sulfate and the concentrated crude product was further purified by flash silica chromatography. Product was crystallized from methylene chloride/hexane to give 1.1 g of 1-methyl-6-trifluoroacetylaminoindole.

c) 200 mg of 1-methyl-6-trifluoroacetylaminoindole was taken into 5 ml of ether and cooled to 0°C. It was treated with 0.485 ml 2.0 M oxalyl chloride / methylene dichloride and stirred at 0°C for 2 h. The yellow crystals were collected and washed with ether and dried in vacuo to yield 240 mg of (6-trifluoroacetylamino-1-methyl-1H-indol-3-yl)-oxo-acetyl chloride.

d) 240 mg of (6-trifluoroacetylamino-1-methyl-1H-indol-3-yl)-oxo-acetyl chloride and 181 mg of 2-(1-methyl-6-nitro-1H-indol-3-yl)-acetimidic acid

isopropyl ester hydrochloride were stirred in methylene chloride with 494 mg triethylamine at 0°C for 2 hrs, then at room temperature overnight. The reaction mix was diluted with methylene chloride and washed with cold 0.5N hydrochloric acid and 5% brine. It was back extracted with methylene chloride and the organic extracts were passed over a plug of magnesium sulfate and concentrated. The crude residue was taken into methylene chloride and treated with 244 mg of p-toluene sulfonic acid for 5 hrs at room temperature. It was diluted with methylene chloride and a few drops of methanol was added to solubilize. It was washed with 10% sodium bicarbonate and water and back extracted with methylene chloride. The organic extracts were dried over magnesium sulfate and concentrated. The crude material was further purified by prep LC (20% ethyl acetate/methylene chloride) to yield 48 mg of N-{1-methyl-3-[4-(1-methyl-6-nitro-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-3-yl}-trifluoroacetamide as a red-orange solid.

15 e) 120 mg of N-{1-methyl-3-[4-(1-methyl-6-nitro-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-3-yl}-trifluoro-acetamide was taken into 8 ml water/ methanol (1/1) and treated with 240 mg potassium carbonate and warmed to 45°C for 5 hours. It was cooled to room temperature and taken into methylene chloride and washed with water and back extracted with methylene chloride. The organic extracts were dried over magnesium sulfate, filtered and concentrated to near dryness. 25 ml of acetonitrile were added and it was concentrated to 5 ml, diluted with 25 ml acetonitrile / water (1/1) and acidified with .25 ml 1.0 N hydrochloric acid. It was concentrated to remove acetonitrile and lyophilized to yield 50 mg of 3-(6-amino-1-methyl-1H-indol-3-yl)-4-(1-methyl-6-nitro-1H-indol-3-yl)-pyrrole-2,5-dione as a red orange solid.

EXAMPLE 9

30 N-{1-Methyl-3-[4-(1-methyl-6-nitro-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-3-yl}-acetamide

(6-Acetylamino-1-methyl-1H-indol-3-yl)-oxo-acetyl chloride was prepared from 6-amino-1-methyl-1H-indole utilizing procedures similar to those described in Example 8b) and c). It was then converted to N-{1-methyl-3-[4-(1-methyl-6-nitro-

34

1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-3-yl}-acetamide utilizing a procedure similar to that described in Example 8d).

EXAMPLE 10

5

3-(6-Amino-1-methyl-1H-indol-3-yl)-4-(6-[4-azido-3-iodo-phenyl]-2-oxo-butyl)-1-methyl-1H-indol-3-yl)-pyrrole-2,5-dione

10 3,4-Bis-(1-methyl-6-amino-1H-indol-3-yl)-pyrrole-2,5-dione (40 mg, 0.1 mM) was dissolved in tetrahydrofuran (3 ml) and cooled to 0°C. 3-(4-azido-3-iodo-phenyl)-propionic acid (29.6 mg, 0.09 mM) was added followed by N-hydroxybenztriazole (16 mg, 0.1 mM) and diisopropylcarbodiimide (16 µl, 0.1 mM). The reaction mixture was stirred at 0°C for 5 hrs., then concentrated and purified by column chromatography in 3% methanol /methylene chloride to give 3-(6-amino-1-methyl-1H-indol-3-yl)-4-(6-[4-azido-3-iodo-phenyl]-2-oxo-butyl)-1-methyl-1H-indol-3-yl)-pyrrole-2,5-dione (18.7 mg, 29%).

15

EXAMPLE 11

20

In a manner similar to that described in Example 10, the following compounds were prepared:

25

a) 3-(6-Fluoro-1-methyl-1H-indol-3-yl)-4-(6-[4-azido-3-iodo-phenyl]-2-oxo-butyl)-1-methyl-1H-indol-3-yl)-pyrrole-2,5-dione was prepared from 3-(6-fluoro-1-methyl-1H-indol-3-yl)-4-(1-methyl-6-amino-1H-indol-3-yl)-pyrrole-2,5-dione.

30

b). 3-(6-Methoxy-1-methyl-1H-indol-3yl)-4-(6-[4-azido-3-iodo-phenyl]-2-oxo-butyl)-1-methyl-1H-indol-3-yl)-pyrrole-2,5-dione was prepared from 3-(6-methoxy-1-methyl-1H-indol-3-yl)-4-(1-methyl-6-amino-1H-indol-3-yl)-pyrrole-2,5-dione.

c) N-{3-[4-(6-Formylamino-1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1-methyl-1H-indol-6-yl}-formamide was prepared from 3,4-bis-(1-methyl-6-amino-1H-indol-3-yl)-pyrrole-2,5-dione and formic acid.

35

d) N-{3-[4-(6-Methoxy-1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1-methyl-1H-indol-6-yl}-formamide was prepared from 3-(6-methoxy-1-methyl-1H-indol-3-yl)-4-(1-methyl-6-amino-1H-indol-3-yl)-pyrrole-2,5-dione and formic acid.

5

EXAMPLE 12

N-{3-[4-(6-Acetylamino-1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1-methyl-1H-indol-6-yl}-acetamide

10

3,4-Bis-(1-methyl-6-amino-1H-indol-3-yl)-pyrrole-2,5-dione (50 mg, 0.13 mM) was dissolved in tetrahydrofuran (2.5 ml) and cooled to 0°C. Triethylamine (38.5 µl, 0.27 mM) was added followed by acetyl chloride (19.4 µl, 0.27 mM). The reaction was stirred for 30 min, then concentrated. The reaction mixture was dissolved in chloroform, washed with 0.1 N hydrochloric acid and the organic layer was dried over magnesium sulfate, filtered and concentrated. The product was purified by column chromatography in 5% methanol/ethyl acetate to give N-{3-[4-(6-acetylamino-1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1-methyl-1H-indol-6-yl}-acetamide (14 mg, 23%).

15

EXAMPLE 13

N-{3-[4-(6-Methoxy-1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1-methyl-1H-indol-6-yl}-acetamide

20

In a manner similar to that described in Example 12, N-{3-[4-(6-methoxy-1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1-methyl-1H-indol-6-yl}-acetamide was obtained from 3-(6-methoxy-1-methyl-1H-indol-3-yl)-4-(1-methyl-6-amino-1H-indol-3-yl)-pyrrole-2,5-dione.

25

30

EXAMPLE 14

3-(6-Methoxy-1-methyl-1H-indol-3-yl)-4-(1-methyl-6-methyl-amino-1H-indol-3-yl)-pyrrole-2,5-dione

5

- a) 6-Aminoindole was prepared from 6-nitroindole in a manner similar to that described in Example 5b.
- 10 b) N-Methyl-(1-methyl-1H-indol-6-yl)-amine was prepared from 6-amino indole in a manner similar to that described in Example 1a.
- c) Methyl-(1-methyl-1H-indol-6-yl)-amine (50 mg, 0.31mM) was dissolved in methylene chloride (2ml) and cooled to 0°C. Triethylamine (55 µl, 0.39 mM) was added followed by benzylchloroformate (52 µl, 0.39 mM). The reaction was stirred 15 at room temperature for 1 hr. The reaction mixture was washed with 0.1 N hydrochloric acid and the organic was dried over magnesium sulfate, filtered and concentrated. The product was purified by column chromatography in 25% ethyl acetate/hexane to give methyl-(1-methyl-1H-indol-6-yl)-carbamic acid benzyl ester (67 mg, 73%).
- 20 d) (3-Chloroxalyl-1-methyl-1H-indol-6-yl)-methyl-carbamic acid benzyl ester was prepared from methyl-(1-methyl-1H-indol-6-yl)-carbamic acid benzyl ester in a procedure similar to that described in Example 1b.
- 25 e) 2-(6-Methoxy-1-methyl-1H-indol-3-yl)-acetimidic acid isopropyl ester hydrochloride, prepared as in Example 1f, and (3-chlorocarbonecarbonyl-1-methyl-1H-indol-6-yl)-methyl-carbamic acid benzyl ester were coupled in a manner similar to that described in Example 1g to give {3-[4-(6-methoxy-1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1-methyl-1H-indol-6yl}-methyl-carbamic acid benzyl ester.
- 30 f) {3-[4-(6-Methoxy-1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1-methyl-1H-indol-3-yl}-methyl-carbamic acid benzyl ester (26mg, 0.048 mMole), was dissolved in toluene (4ml). Pd/C (10 mg x 10%, 0.009 mM) was added and the reaction mixture was shaken on a Parr Hydrogenator at 50 psi.

37

for 13 hrs. The crude reaction mixture was filtered through a bed of Celite and concentrated to give 3-(6-methoxy-1-methyl-1H-indol-3-yl)-4-(1-methyl-6-methylamino-1H-indol-3-yl)-pyrrole-2,5-dione (16 mg, 81%).

5

EXAMPLE 15

TABLET FORMULATION

Item	Ingredients	mg/Tablet					
		5mg	25mg	100mg	250mg	500mg	750mg
1	Compound A	5	25	100	250	500	750
2	Anhydrous Lactose	103	83	35	19	38	57
3	Croscarmellose Sodium	6	6	8	16	32	48
4	Povidone K30	5	5	6	12	24	36
5	Magnesium Stearate	1	1	1	3	6	9
	Total Weight	120	120	150	300	600	900

10 Compound A represents a compound of the invention.

Manufacturing Procedure:

1. Mix Items 1, 2 and 3 in a suitable mixer for 15 minutes.
- 15 2. Granulate the powder mix from Step 1 with 20% Povidone K30 Solution (Item 4).
3. Dry the granulation from Step 2 at 50°C.
4. Pass the granulation from Step 3 through a suitable milling equipment.
5. Add the Item 5 to the milled granulation Step 4 and mix for 3 minutes.
- 20 6. Compress the granulation from Step 5 on a suitable press.

EXAMPLE 16

CAPSULE FORMULATION

Item	Ingredients	mg/Tablet				
		5mg	25mg	100mg	250mg	500mg
1	Compound A	5	25	100	250	500
2	Hydrous Lactose	159	123	148	--	--
3	Corn Starch	25	35	40	35	70
4	Talc	10	15	10	12	24
5	Magnesium Stearate	1	2	2	3	6
	Total Fill Weight	200	200	300	300	600

5

Manufacturing Procedure:

1. Mix Items 1, 2 and 3 in a suitable mixer for 15 minutes.
2. Add Items 4 and 5 and mix for 3 minutes.
- 10 3. Fill into a suitable capsule.

EXAMPLE 17

INJECTION SOLUTION/EMULSION PREPARATION

15

Item	Ingredient	mg/ml
1	Compound A	1 mg
2	PEG 400	10-50 mg
20	Lecithin	20-50 mg
4	Soy Oil	1-5 mg
5	Glycerol	8-12 mg
6	Water	q.s.ad 1 ml

Manufacturing Procedure:

1. Dissolve Item 1 in Item 2
2. Add Items 3, 4 and 5 to Item 6 and mix until dispersed, then
5 homogenize.
3. Add the solution from step 1 to the mixture from step 2 and homogenize
until
the dispersion is translucent.
4. Sterile filter through a 0.2 μm filter and fill into vials.

10

EXAMPLE 18

INJECTION SOLUTION/EMULSION PREPARATION

15	<u>Item</u>	<u>Ingredient</u>	<u>mg/ml</u>
	1	Compound A	1 mg
	2	Glycofurool	10-50 mg
	3	Lecithin	20-50 mg
20	4	Soy Oil	1-5 mg
	5	Glycerol	8-12 mg
	6	Water	q.s. ad 1 ml

Manufacturing Procedure:


25

1. Dissolve Item 1 in Item 2
2. Add Items 3, 4 and 5 to Item 6 and mix until dispersed, then
homogenize.
3. Add the solution from step 1 to the mixture from step 2 and homogenize
until
the dispersion is translucent.
4. Sterile filter through a 0.2 μm filter and fill into vials.

30

Claims

1. A compound of the formula



5

I

wherein

R¹ and R^{1'} are independently alkyl, aryl, alkenyl or alkynyl;

R² and R^{2'} are independently hydrogen or alkyl;

10

R⁴, R⁵, R⁶, R⁷, R^{4'}, R^{5'}, R^{6'}, and R^{7'} each independently are hydrogen, CH₂OCR⁸, CO₂R⁹, CH₂OR¹⁰, CHO, CH₂NR¹¹R¹², CON(R¹³)₂, halogen, cyano, aryl, alkyl, hydroxy, alkoxy, aryloxy, haloalkyl, nitro, amino, aralkyloxy, acylamino, monoalkylamino, dialkylamino, thio, alkylthio, alkylsulphinyl, alkylsulphonyl, arylsulphinyl, azide, phosphate or phosphonate provided that at least one of R⁴, R⁵, R⁶ and R⁷ and at least one of R^{4'}, R^{5'}, R^{6'}, and R^{7'} are other than hydrogen, with the proviso that when R⁶ is methoxy, R⁵ or R^{5'} are not methoxy;

15

R⁸ is alkyl or aryl;

R⁹ is alkyl or aryl;

R¹⁰ is hydrogen, alkyl or aryl;

20

R¹¹ and R¹² are independently hydrogen, alkyl, aryl, aralkyl or acyl;

R¹³ is hydrogen, alkyl, aryl or aralkyl; and

25

one of X and Y signifies O and the other signifies S, (H,OH) or (H,H); and pharmaceutically acceptable prodrugs therefor or pharmaceutically acceptable salts of acidic compounds of formula I with bases or basic compounds of formula I with acids.

41

2. A compound of Claim 1, wherein R¹ and R^{1'} are independently alkyl.

3. A compound of Claim 2, wherein R¹ and R^{1'} are methyl.

5 4. A compound of Claim 1, wherein R² and R^{2'} are each hydrogen.

5. A compound of Claim 1, wherein at least one of R⁴, R⁵, R⁶
and R⁷, and at least one of R^{4'}, R^{5'}, R^{6'} and R^{7'} are independently nitro, alkoxy, alkyl,

10 halogen, cyano, CH_2OCR^8 , CO_2R^9 , $\text{CH}_2\text{OR}^{10}$, $\text{CH}_2\text{NR}^{11}\text{R}^{12}$, CHO, $\text{CON}(\text{R}^{13})_2$,
alkylthio or aralkyloxy.

6. A compound of Claim 5, wherein at least one of R⁴, R⁵, R⁶
and R⁷ and at least one of R^{4'}, R^{5'}, R^{6'} and R^{7'} are cyano, CH_2OCR^8 , CO_2R^9 ,
15 $\text{CH}_2\text{OR}^{10}$, $\text{CH}_2\text{NR}^{11}\text{R}^{12}$, CHO or $\text{CON}(\text{R}^{13})_2$.

7. A compound of Claim 5, wherein one of R⁴, R⁵, R⁶
and R⁷ and one of R^{4'}, R^{5'}, R^{6'} and R^{7'} are nitro, alkoxy, alkyl, halogen, cyano,
15 CH_2OCR^8 , CO_2R^9 , $\text{CH}_2\text{OR}^{10}$, $\text{CH}_2\text{NR}^{11}\text{R}^{12}$, CHO, alkylthio, aralkyloxy or
CON(R¹³)₂ and the others are hydrogen.

8. A compound of Claim 5, wherein R¹ and R^{1'} are alkyl, and R² and
R^{2'} are hydrogen.

25 9. A compound of Claim 7, wherein R⁸ is alkyl, R⁹ is alkyl, R¹⁰ is
hydrogen or alkyl, R¹¹ is alkyl, R¹² is alkyl, and R¹³ is alkyl.

10. A compound of Claim 6, wherein R¹ and R^{1'} are alkyl, and R² and
R^{2'} are hydrogen.

48

11. A compound of Claim 9, wherein R^{10} is alkyl.

12. A compound of Claim 9, wherein R^6 and R^6 are nitro,



alkoxy, alkyl, halogen, cyano, CH_2OCR^8 , CO_2R^9 , CH_2OR^{10} , $CH_2NR^{11}R^{12}$, alkylthio
5 aralkyloxy, CHO or $CON(R^{13})_2$, and R^4 , R^5 , R^7 and R^4 , R^5 and R^7 are hydrogen.

13. A compound of Claim 8, wherein R^6 and R^6 are nitro,



alkoxy, alkyl, halogen, cyano, CH_2OCR^8 , CO_2R^9 , CH_2OR^{10} , $CH_2NR^{11}R^{12}$, alkylthio,
aralkyloxy, CHO or $CON(R^{13})_2$, and R^4 , R^5 , R^7 and R^4 , R^5 and R^7 are hydrogen.

10

14. A compound of Claim 2, wherein R^2 and R^2 are each hydrogen and at least one of R^4 , R^5 , R^6 and R^7 is amino, acylamino, monoalkylamino or dialkylamino.

15

15. A compound of Claim 14, wherein R^6 is amino, acylamino, monoalkylamino or dialkylamino and at least one of R^4 , R^5 and R^6 is



CH_2OCR^8 , CO_2R^9 , CH_2OR^{10} , CHO, $CH_2NR^{11}R^{12}$, $CON(R^{13})_2$, halogen, cyano, aryl, alkyl, hydroxy, alkoxy, aryloxy, haloalkyl, nitro, amino, aralkyloxy, acylamino, monoalkylamino, dialkylamino, thio, alkylthio, alkylsulphanyl, alkylsulphonyl, arylsulphanyl, azide, phosphate or phosphonate.

20

16. A compound of Claim 15, wherein R^6 is amino, acylamino, monoalkylamino or dialkylamino and R^6 is



CH_2OCR^8 , CO_2R^9 , CH_2OR^{10} , CHO, $CH_2NR^{11}R^{12}$, $CON(R^{13})_2$, halogen, cyano, aryl, alkyl, hydroxy, alkoxy, aryloxy, haloalkyl, nitro, amino, aralkyloxy, acylamino, monoalkylamino, dialkylamino, thio, alkylthio, alkylsulphanyl, alkylsulphonyl, arylsulphanyl, azide, phosphate or phosphonate.

25

17. The compound of Claim 1 which is 3-(6-amino-1-methyl-1H-indol-3-yl)-4-(6-fluoro-1-methyl-1H-indol-3-yl)-pyrrole-2,5-dione.

18. The compound of Claim 1 which is 3-(6-amino-1-methyl-1H-indol-3-yl)-4-(6-bromo-1-methyl-1H-indol-3-yl)-pyrrole-2,5-dione.
- 5 19. The compound of Claim 1 which is 3-(6-amino-1-methyl-1H-indol-3-yl)-4-(6-methoxy-1-methyl-1H-indol-3-yl)-pyrrole-2,5-dione.
20. The compound of Claim 1 which is 3-(6-amino-1-methyl-1H-indol-3-yl)-4-(1-methyl-6-nitro-1H-indol-3-yl)-pyrrole-2,5-dione.
- 10 21. The compound of Claim 1 which is 3-[4-(6-amino-1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1-methyl-1H-indole-6-carbonitrile.
- 15 22. The compound of Claim 1 which is 3-(6-methoxy-1-methyl-1H-indol-3-yl)-4-(1-methyl-6-nitro-1H-indol-3-yl)-pyrrole-2,5-dione.
23. The compound of Claim 1 which is 3-(6-benzyloxy-1-methyl-1H-indol-3-yl)-4-(1-methyl-6-nitro-1H-indol-3-yl)-pyrrole-2,5-dione.
- 20 24. The compound of formula 1 which is 3-(6-chloro-1-methyl-1H-indol-3-yl)-4-(1-methyl-6-nitro-1H-indol-3-yl)-pyrrole-2,5-dione.
- 25 25. The compound of Claim 1 which is 3-(1,6-dimethyl-1H-indol-3-yl)-4-(6-methoxy-1-methyl-1H-indol-3-yl)-pyrrole-2,5-dione.
26. The compound of Claim 1 which is 3-(1,6-dimethyl-1H-indol-3-yl)-4-(1-methyl-6-nitro-1H-indol-3-yl)-pyrrole-2,5-dione.
- 30 27. The compound of Claim 1 which is 3,4-bis-(6-methoxy-1-methyl-1H-indol-3-yl)-pyrrole-2,5-dione.
28. The compound of Claim 1 which is 3-(6-fluoro-1-methyl-1H-indol-3-yl)-4-(1-methyl-6-nitro-1H-indol-3-yl)-pyrrole-2,5-dione.

44

29. The compound of Claim 1 which is 3,4-bis-(1-methyl-6-nitro-1H-indol-3-yl)-pyrrole-2,5-dione.

5 30. The compound of Claim 1 which is 3-(6-amino-1-methyl-1H-indol-3-yl)-4-(1-methyl-6-methylsulfanyl-1H-indol-3-yl)- pyrrole-2,5-dione.

31. The compound of Claim 1 which is 3-(6-amino-1-methyl-1H-indol-3-yl)-4-(1,6-dimethyl-1H-indol-3-yl)- pyrrole-2,5-dione.

10 32. The compound of Claim 1 which is N-{3-[4-(6-methoxy-1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1-methyl-1H-indol-6-yl}-acetamide.

15 33. The compound of Claim 1 which is 3-(6-methoxy-1-methyl-1H-indol-3-yl)-4-(1-methyl-6-methyl-amino-1H-indol-3-yl)-pyrrole-2,5-dione.

34. The compound of Claim 1 which is 3-[4-(1,6-dimethyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrole-3-yl]-1-methyl-1H-indole-6- carbonitrile.

20 35. The compound of Claim 1 which is 3-(1-methyl-6-methylsulfanyl-1H-indol-3-yl)-4-(1-methyl-6-nitro-1H-indol-3-yl)-pyrrole-2,5-dione.

25 36. The compound of Claim 1 which is 3-{6-[2-(2-ethoxy-ethoxy)-ethoxy]-1-methyl-1H-indol-3-yl}-4-(1-methyl-6-nitro-1H-indol-3-yl)-pyrrole-2,5-dione.

30 37. A pharmaceutical composition comprising an effective amount of a compound of the formula I or of a pharmaceutically acceptable prodrug therefor or of a pharmaceutically acceptable salt of an acidic compound of formula I with a base or of a basic compound of formula I with an acid as claimed in any one of Claims 1-36 and an inert carrier.

38. Use of a compound as claimed in any one of Claims 1-36 for the inhibition of cell proliferation or for the preparation of corresponding medicaments.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 97/03888

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07D403/14 A61K31/40

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 397 060 A (GÖDECKE AG) 14 November 1990 see examples 44,49 -----	1,37,38
A	EP 0 328 026 A (F. HOFFMANN-LA ROCHE & CO.) 16 August 1989 * examples 1,6,7,8,16,17,19,30, etc. * -----	1,37,38



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

Z document member of the same patent family

1

Date of the actual completion of the international search 30 October 1997	Date of mailing of the international search report 07.11.97
--	--

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Van Bijlen, H

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 97/03888

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP 397060 A	14-11-90	DE 3914764 A		08-11-90
		DE 3942991 A		04-07-91
		AU 634541 B		25-02-93
		AU 5466690 A		08-11-90
		CA 2015996 A		05-11-90
		JP 2306974 A		20-12-90
		NO 179748 B		02-09-96
		PT 93947 B		29-11-96
		US 5380746 A		10-01-95
		US 5516915 A		14-05-96
<hr/>				
EP 328026 A	16-08-89	AU 2965889 A		10-08-89
		CA 1320194 A		13-07-93
		CZ 8900752 A		13-12-95
		DK 55889 A		11-08-89
		ES 2054890 T		16-08-94
		FI 96861 B		31-05-96
		IE 63489 B		03-05-95
		IL 89167 A		27-02-94
		JP 1233281 A		19-09-89
		JP 1994298 C		22-11-95
		JP 7030071 B		05-04-95
		MX 14871 A		01-09-93
		PT 89661 B		28-02-94
		SU 1799382 A		28-02-93
		US 5057614 A		15-10-91
<hr/>				